Our pipeline

We focus our development resources on projects within our core therapeutic areas of Neuroscience, Rare Diseases, Gastrointestinal and Regenerative Medicine, as well as early development projects in additional therapeutic areas.

Total R&D expenditures of $965.5 million, $770.7 million and $661.5 million were incurred in the years ended December 31, 2012, 2011 and 2010 respectively.

Disease AreaProjectDevelopment StatusTerritorial rights
Neuroscience
ADHDINTUNIV (extended release guanfacine)Registration in Canada (Regulatory submission in Q4 2011)Global
ADHD in children and adolescentsINTUNIVPhase 3 in EU (entered Phase 3 in Q2 2010)Global
Adjunctive therapy in Major Depressive Disorder (MDD)LDX (lisdexamfetamine dimesylate)Phase 3  in US (entered Phase 3 in Q4 2011)Global
Binge Eating Disorder (BED) in adultsLDX (lisdexamfetamine dimesylate)Phase 3 in US (entered Phase 3 in Q4 2012)Global
ADHD in children and adolescentsLDX (lisdexamfetamine dimesylate)Phase 2-ready in JapanGlobal(1)
ADHD in children and adolescentsINTUNIVPhase 3-ready in JapanGlobal(1)
 
Rare Diseases
ACE inhibitor-induced AngioedemaFIRAZYRRegistration in Europe
Phase 3 ready in US
Global
Hunter Syndrome with CNS symptomsHGT2310Phase 1/ 2 completed and preparation is underway for a Phase 3 trialGlobal(2)
Sanfilippo A Syndrome (MPS IIIA)HGT1410Phase 1/ 2 completed and preparation is underway for a Phase 2b trialGlobal
Metachromatic Leukodystrophy (“MLD”)HGT1110Phase 1/ 2Global
 
Gastrointestinal
Chronic Constipation (Males)RESOLOR (prucalopride)Phase 3 in EU (entered Phase 3 in Q4 2010) Europe
Chronic ConstipationSPD555 (prucalopride)Phase 3-ready in USUS
Refractory gastroesophageal reflux disease (“rGERD”)SPD557Phase 2Europe and North America
 
Regenerative Medicine
Epidermolyis Bullosa (EB)ABH001Phase 3 in US (entered Phase 3 in Q4 2012)Global
Acute Vascular RepairSRM003Phase 2Global
 
Other therapeutic area
Essential thrombocythaemiaXAGRIDPhase 3 in Japan (entered Phase 3 in Q4 2010)Global
Dry eye diseaseSPD606 (lifitegrast)Phase 3Global
Chronic Iron-overloadSPD602 (FBS 0701)Phase 2Global
Prevention of retinopathy of prematurity (ROP)HGT-ROP-001Phase 2Global

(1) Under co-development with Shionogi as a result of a license and collaboration agreement. 
(2) Genzyme has rights to manage marketing and distribution in Japan and certain other Asia Pacific countries under a license with Shire.